Dr. Carlos Arteaga reviewed the PI3K/AKT/mTOR pathway in breast cancer, highlighting PIK3CA mutations as key drivers of tumor growth. He discussed PI3Kα inhibitors, combination strategies with endocrine and CDK4/6 therapies, and emerging mutant-selective inhibitors to improve efficacy and reduce toxicity.

Dr. Irene Kang reviewed PI3K-targeted therapies in breast cancer, highlighting improved progression-free survival with alpelisib, capivasertib, and inovolisib in PIK3CA-mutated disease. She also discussed promising results with pan-PI3K inhibitor gedatolisib and emerging mutant-selective PI3K inhibitors.

Dr. Stephen Chia reviewed AKT inhibition with endocrine therapy, highlighting improved progression-free survival after CDK4/6 inhibitors, especially in AKT-altered tumors. He emphasized post-CDK4/6 genotyping to identify patients who may benefit from AKT-targeted therapies.

Dr. Reshma Mahtani reviewed emerging PI3K/AKT therapies, highlighting mutant-selective inhibitors that may improve efficacy while reducing toxicities such as hyperglycemia, rash, and diarrhea. Early trials show promising response rates and progression-free survival, with phase 3 studies underway.

The panel discussed the potential benefits of using everolimus, an older drug, in combination with newer drugs like gedatolisib. They also debated the efficacy of triplets versus doublets in different patient populations, noting that triplets may be more effective in PIK3CA WT tumors. The discussion emphasized the importance of early intervention and tailored treatment approaches.